In this exploratory biomarker analysis of samples obtained from clinical trials evaluating T-DXd efficacy in patients with gastric cancer (2, 13–15), we assessed HER2 biomarker status and its association with clinical outcomes. Here, ERBB2 is linked to gastric cancer.